Health Care [ 11/12 ] | Pharmaceuticals [ 50/75 ]
NASDAQ | Common Stock
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.58 Increased by +4.92% | -0.52 Decreased by -11.54% |
| May 8, 24 | -0.55 Increased by +1.79% | -0.42 Decreased by -30.95% |
| Mar 7, 24 | -0.33 Increased by +71.55% | -0.49 Increased by +32.65% |
| Nov 1, 23 | -0.33 Increased by +32.65% | -0.51 Increased by +35.29% |
| Aug 2, 23 | -0.61 Decreased by -17.31% | 0.60 Decreased by -201.67% |
| May 3, 23 | -0.56 Increased by 0.00% | -0.68 Increased by +17.65% |
| Mar 2, 23 | -1.16 Decreased by -96.61% | -0.61 Decreased by -90.16% |
| Nov 2, 22 | -0.49 Increased by +15.52% | -0.70 Increased by +30.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 9.48 M Increased by +4.09% | -30.83 M Decreased by -34.49% | Decreased by -325.27% Decreased by -29.21% |
| Mar 31, 24 | 11.68 M Increased by +52.08% | -29.28 M Decreased by -35.66% | Decreased by -250.63% Increased by +10.79% |
| Dec 31, 23 | 14.03 M Increased by +33.18% | -14.10 M Increased by +78.02% | Decreased by -100.51% Increased by +83.50% |
| Sep 30, 23 | 15.20 M Increased by +51.84% | -12.61 M Increased by +31.61% | Decreased by -82.96% Increased by +54.96% |
| Jun 30, 23 | 9.11 M Decreased by -21.27% | -22.92 M Decreased by -18.11% | Decreased by -251.73% Decreased by -50.02% |
| Mar 31, 23 | 7.68 M Decreased by -17.33% | -21.59 M Increased by +4.21% | Decreased by -280.96% Decreased by -15.87% |
| Dec 31, 22 | 10.53 M Decreased by -8.76% | -64.15 M Decreased by -230.13% | Decreased by -609.05% Decreased by -261.82% |
| Sep 30, 22 | 10.01 M Increased by +10.52% | -18.44 M Decreased by -10.46% | Decreased by -184.20% Increased by +0.05% |